Piramal Pharma to discuss Q1 FY2027 results on Jul 30

Piramal Pharma Limited will discuss its Q1 FY2027 financial performance during a conference call scheduled for July 30, 2026. The earnings call, set to take place from 9:30 AM to 10:15 AM IST, will allow the company's management to present the quarterly results to investors and analysts. This initiative is undertaken pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has arranged specific dial-in numbers and access times for participants across different global regions to facilitate attendance. The discussion will cover the operational and financial highlights for the first quarter of the fiscal year 2027.

Conference Call Details

The following table outlines the access details for the conference call:

Event	Location & Time	Telephone Number
Conference call on 30th July 2026	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 12:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 05:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – Click Here

Company Overview

Piramal Pharma Limited offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities. The company operates through three primary business verticals: Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business. Additionally, the company has a joint venture, Abbvie Therapeutics India Private Limited, and a strategic minority investment in Yapan Bio Private Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.24%	+3.71%	+7.33%	+19.72%	-11.59%	-2.31%

HDFC Mutual Fund reduced its shareholding in piramal pharma by 2.005% to 7.015% of the paid-up equity share capital as of July 14, 2026. The divestment involved the sale of 26,688,471 equity shares through the open market. This change follows a previous disclosure where the fund held a 9.034% stake as of June 26, 2025.

The transaction was disclosed to the stock exchanges in accordance with Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The letter was submitted by Dinesh Bhakade, Lead - Compliance Governance at HDFC Asset Management Company Limited, the investment manager for the schemes of HDFC Mutual Fund.

Shareholding Details

The reduction in stake was executed across several schemes managed by HDFC Mutual Fund, including the HDFC BSE 500 ETF, HDFC Focused Fund, and HDFC Flexi Cap Fund. The acquirer clarified that it does not belong to the promoter or promoter group of the target company.

The following table outlines the changes in the shareholding pattern:

Description	Number of Shares	% of Total Share Capital
Holding Before Sale
Shares carrying voting rights	12,00,82,126	9.020
Details of Sale
Shares sold	2,66,88,471	2.005
Holding After Sale
Shares carrying voting rights	9,33,93,655	7.015

Capital Structure

The paid-up equity share capital of Piramal Pharma Limited was reported at ₹13,31,34,81,300, comprising 1,33,13,48,130 equity shares of ₹10 each. This capital base remained unchanged before and after the transaction. The shares of the company are listed on BSE Limited and the National Stock Exchange of India Limited.